Clinical trialPhase 3
Lp(a)HORIZON (pelacarsen)
NCT04023552
Randomized double-blind placebo-controlled, 8 323 участника с CVD и Lp(a) ≥70 mg/dL.
Also in the catalogue
- ACCLAIM-Lp(a)Clinical trial
- OCEAN(a)-OutcomesClinical trial
- PelacarsenDrug
- STX-1150 (Tune/CasX epigenetic PCSK9 silencing), first-in-humanClinical trial
- Long-term follow-up of gene-editing recipients (up to 15 years)Clinical trial
- ACCLAIM-CTAClinical trial
Scales
Identifiers
- NCT
- NCT04023552
Original sources
Details
- Phase
- Phase 3
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.